FDA and EMA waive paediatric studies for Shanton’s gout candidate
Under an agreement reached with the EMA on a paediatric investigation plan (PIP), the clinical-stage biotechnology company received a full, product-specific waiver. The decision applies across all paediatric
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.